Cergentis
Menu

Home

Empowering Precision Medicine

Finding all relevant mutations in a single test

  • Targeted complete next generation sequencing of any locus or (trans)gene of interest
  • Detection of all SNVs and structural variants
  • Identification of all gene fusions and clinically relevant mutations in cancer genes
  • Kits & services

 

GET IN TOUCH

Discover our applications
Genetic engineering
Find out more
Clinical Genetics
Find out more

"Targeted Locus Amplification enables fast identification of new chromosomal rearrangements and genomic breakpoint sequences in human T-ALL and unraveled a higher complexity of chromosomal translocations of known T-ALL oncogenes as thus far appreciated.”

Ghent University
Prof. Dr. Pieter van Vlierberghe - Center for Medical Genetics

"TLA has become an indispensable tool to characterize transgene insertion events and complex gene targeting approaches."

Taconic
Dr. Jochen Welcker - Director Molecular Biology & Scientific Development

"We use TLA to sequence gene fusions and other rearrangements in genes of interest. We have been impressed by the quality of TLA and Cergentis' work and are testing the use of identified breakpoint sequences as targets for personalised minimal residual disease tests."

Princess Máxima Center for Pediatric Oncology
Dr. Roland Kuiper - PI

"Unknown translocation partners that drive expression of oncogenes as consequence of cryptic or previous unidentified chromosomal rearrangements were identified in T-cell leukemia patients using Targeted Locus Amplification.”

Princess Máxima Center for Pediatric Oncology
Dr. Jules Meijerink - PI

"Cergentis quickly determined transgene insertion for three out of three lines along with providing information on deletions and rearrangements in chromosomal DNA at the site. The service was quick, accurate and reasonably priced, and reports were complete and helpful.”

Harvard University
Prof. Dr. Joshua Sanes - Department of Molecular and Cellular Biology

"Thank you so much. Data about the structural changes in our patient are very clear. Really powerful technology!”

University of Turin
Prof. Dr. Alfredo Brusco - Department of Medical Sciences

"TLA outperforms traditional methods used in CHO cell line characterisation and provides higher resolution and sensitivity.”

Synthon
Dr. Stefanie Bartels - Project Leader Cell Line Development

"TLA is a highly efficient method for mapping the insertion site of any transgene.”

Genentech
Dr. Søren Warming - Associate Director/Senior Scientist

"TLA analysis has proven to be very useful to quality control genetically engineered cell lines”

AstraZeneca
Dr. John Wiseman - Associate Director

"Working with the team at Cergentis has allowed us to add an extra dimension to the analysis of our stable cell lines. Their understanding of our needs combined with the reliability and reproducibility of TLA analysis has resulted in a number of successful projects."

Teva Pharmaceuticals
Dr. Teresa Domagala

LATEST NEWS

 

UPCOMING EVENTS

 

© 2012-2020 Cergentis B.V. All rights reserved.
For Research Use Only.Not for use in diagnostic procedures.